Tirzepatide is a once-weekly GIP (glucose-dependent insulinotropic polypeptide) receptor and GLP-1 (glucagon-like peptide-1) receptor agonist, representing a new class of medicines studied for the treatment of obesity. Tirzepatide is a single peptide that triggers the body's receptors for GIP and GLP-1, two natural incretin hormones. Cyanocobalamin will help increase energy.
GIP has decreased food intake and increased energy expenditure, resulting in weight reductions. Combined with a GLP-1 receptor agonist, it has a more significant effect on glucose and body weight effects.
Substantial A1C reductions
Boosted weight loss
Improvements in cardiometabolic measures
Less side effects than Semaglutide
Less adverse effects on gastric indigestion
Providing weight loss results comparable to bariatric surgery